Literature DB >> 26734651

Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.

Mehdi Rashighi1, John E Harris1.   

Abstract

Entities:  

Year:  2015        PMID： 26734651      PMCID： PMC4690998          DOI： 10.3978/j.issn.2305-5839.2015.11.36

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  34 in total

1.  Etanercept in the treatment of vitiligo.

Authors:  Dimitris Rigopoulos; Stamatis Gregoriou; George Larios; Evi Moustou; Elena Belayeva-Karatza; Dimitris Kalogeromitros
Journal:  Dermatology       Date:  2007       Impact factor: 5.366

2.  Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.

Authors:  Walter Reinisch; Williem de Villiers; László Bene; László Simon; István Rácz; Seymour Katz; István Altorjay; Brian Feagan; Dennis Riff; Charles N Bernstein; Daniel Hommes; Paul Rutgeerts; Antoine Cortot; Michael Gaspari; May Cheng; Tillman Pearce; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2010-02       Impact factor: 5.325

3.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Authors:  Marcus Maurer; Karin Rosén; Hsin-Ju Hsieh; Sarbjit Saini; Clive Grattan; Ana Gimenéz-Arnau; Sunil Agarwal; Ramona Doyle; Janice Canvin; Allen Kaplan; Thomas Casale
Journal:  N Engl J Med       Date:  2013-02-24       Impact factor: 91.245

4.  Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis.

Authors:  Jamie L Harden; Leanne M Johnson-Huang; Maria Francesca Chamian; Edmund Lee; Tillman Pearce; Craig L Leonardi; Asifa Haider; Michelle A Lowes; James G Krueger
Journal:  J Allergy Clin Immunol       Date:  2014-07-29       Impact factor: 10.793

5.  Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo.

Authors:  Ahu Birol; Ucler Kisa; Gulcan Saylam Kurtipek; Fatma Kara; Mukadder Kocak; Emel Erkek; Osman Caglayan
Journal:  Int J Dermatol       Date:  2006-08       Impact factor: 2.736

Review 6.  Depigmentation therapies for normal skin in vitiligo universalis.

Authors:  K M AlGhamdi; A Kumar
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-11-04       Impact factor: 6.166

7.  Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses.

Authors:  S J Rodig; M A Meraz; J M White; P A Lampe; J K Riley; C D Arthur; K L King; K C Sheehan; L Yin; D Pennica; E M Johnson; R D Schreiber
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

Review 8.  Vitiligo.

Authors:  Khaled Ezzedine; Viktoria Eleftheriadou; Maxine Whitton; Nanja van Geel
Journal:  Lancet       Date:  2015-01-15       Impact factor: 79.321

9.  Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita.

Authors:  Yiwei Zhao; Ulrike Gartner; Frances J D Smith; W H Irwin McLean
Journal:  J Invest Dermatol       Date:  2011-03-10       Impact factor: 8.551

10.  A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection.

Authors:  Chung-Her Jenh; Mary Ann Cox; Long Cui; Eva-Pia Reich; Lee Sullivan; Shu-Cheng Chen; David Kinsley; Shiguang Qian; Seong Heon Kim; Stuart Rosenblum; Joseph Kozlowski; Jay S Fine; Paul J Zavodny; Daniel Lundell
Journal:  BMC Immunol       Date:  2012-01-10       Impact factor: 3.615
View more
  21 in total

Review 1.  Vitiligo Pathogenesis and Emerging Treatments.

Authors:  Mehdi Rashighi; John E Harris
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

2.  Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

Authors:  Lucy Y Liu; James P Strassner; Maggi A Refat; John E Harris; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-08-18       Impact factor: 11.527

3.  CYP11A1-derived vitamin D3 products protect against UVB-induced inflammation and promote keratinocytes differentiation.

Authors:  Anyamanee Chaiprasongsuk; Zorica Janjetovic; Tae-Kang Kim; Robert C Tuckey; Wei Li; Chander Raman; Uraiwan Panich; Andrzej T Slominski
Journal:  Free Radic Biol Med       Date:  2020-05-22       Impact factor: 7.376

Review 4.  [Systemic treatment of vitiligo : Balance and current developments].

Authors:  M Meurer; P Ceric-Dehdari
Journal:  Hautarzt       Date:  2017-11       Impact factor: 0.751

Review 5.  The convergence theory for vitiligo: A reappraisal.

Authors:  Roopal V Kundu; Julia M Mhlaba; Stephanie M Rangel; I Caroline Le Poole
Journal:  Exp Dermatol       Date:  2018-06-28       Impact factor: 3.960

Review 6.  Understanding mechanisms of autoimmunity through translational research in vitiligo.

Authors:  James P Strassner; John E Harris
Journal:  Curr Opin Immunol       Date:  2016-10-17       Impact factor: 7.486

7.  The nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligo-inducing phenol monobenzone.

Authors:  Omotayo A Arowojolu; Seth J Orlow; Nada Elbuluk; Prashiela Manga
Journal:  Exp Dermatol       Date:  2017-07       Impact factor: 3.960

8.  Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity.

Authors:  James P Strassner; Mehdi Rashighi; Maggi Ahmed Refat; Jillian M Richmond; John E Harris
Journal:  J Am Acad Dermatol       Date:  2017-03-01       Impact factor: 11.527

Review 9.  Understanding autoimmunity of vitiligo and alopecia areata.

Authors:  Jillian F Rork; Mehdi Rashighi; John E Harris
Journal:  Curr Opin Pediatr       Date:  2016-08       Impact factor: 2.856

Review 10.  The Role of the NKG2D in Vitiligo.

Authors:  Lourdes Plaza-Rojas; José A Guevara-Patiño
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.